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Glucocorticoids suppress Wnt16 
expression in osteoblasts in vitro 
and in vivo
Susanne Hildebrandt1,2,4, Ulrike Baschant1,2, Sylvia Thiele1,2, Jan Tuckermann  3,  
Lorenz C. Hofbauer1,2 & Martina Rauner1,2
Glucocorticoid-induced osteoporosis is a frequent complication of systemic glucocorticoid (GC) 
therapy and mainly characterized by suppressed osteoblast activity. Wnt16 derived from osteogenic 
cells is a key determinant of bone mass. Here, we assessed whether GC suppress bone formation via 
inhibiting Wnt16 expression. GC treatment with dexamethasone (DEX) decreased Wnt16 mRNA 
levels in murine bone marrow stromal cells (mBMSCs) time- and dose-dependently. Similarly, Wnt16 
expression was also suppressed after DEX treatment in calvarial organ cultures. Consistently, mice 
receiving GC-containing slow-release prednisolone pellets showed lower skeletal Wnt16 mRNA levels 
and bone mineral density than placebo-treated mice. The suppression of Wnt16 by GCs was GC-
receptor-dependent as co-treatment of mBMSCs with DEX and the GR antagonist RU-486 abrogated 
the GC-mediated suppression of Wnt16. Likewise, DEX failed to suppress Wnt16 expression in GR 
knockout-mBMSCs. In addition, Wnt16 mRNA levels were unaltered in bone tissue of GC-treated 
GR dimerization-defective GRdim mice, suggesting that GCs suppress Wnt16 via direct DNA-binding 
mechanisms. Consistently, DEX treatment reduced Wnt16 promoter activity in MC3T3-E1 cells. Finally, 
recombinant Wnt16 restored DEX-induced suppression of bone formation in mouse calvaria. Thus, this 
study identifies Wnt16 as a novel target of GC action in GC-induced suppression of bone formation.
Glucocorticoid-induced osteoporosis (GIO) is the most common form of secondary osteoporosis and affects up 
to 50% of patients receiving long-term glucocorticoid (GC) therapy1–3. GIO is characterized by a systemic loss of 
bone mass, microarchitecture and strength, leading to an increased risk of fractures4–8. Due to their potent immu-
nosuppressive characteristics, GCs are widely used for the systemic treatment of inflammatory disorders such as 
rheumatoid arthritis, vasculitis, or inflammatory bowel disease. Thus, there is a great need to further define the 
underlying mechanisms of GIO to specifically target pathways to prevent GIO and the subsequent increase in 
fracture risk.
GIO is characterized by a rapid stimulation of bone resorption, followed by a sustained and profound sup-
pression of bone formation9–11. While physiological concentrations of GCs stimulate osteoblast differentiation12, 
pharmacological doses inhibit osteoblastogenesis13,14. GCs inhibit bone formation by suppressing pro-osteoblastic 
genes such as the key pro-osteogenic transcription factor Runx215,16 and osteocalcin17,18, osteoblast-derived 
pro-osteogenic growth factors and cytokines such as insulin growth factor 1 (IGF-1)19 and IL-1113 as well as by 
suppressing collagen I synthesis16,20–22.
In recent years, the Wnt signaling pathway has emerged as a major regulator of bone homeostasis23. Activation 
of the Wnt pathway leads to high bone mass in mice and humans, whereas inactivation of Wnt signaling leads to 
low bone mass23–25. However, to date the function of specific Wnt ligands in bone homeostasis has not yet been 
completely clarified. Wnt16 is a relatively young member of the Wnt family and is expressed in skeletal tissues26,27. 
Genome-wide association studies have linked missense mutations in the WNT16 gene to lower cortical bone 
thickness, reduced bone mineral density and increased fracture risk in humans28–33. The regulatory role of Wnt16 
on cortical bone and bone strength was further validated using global and osteoblast-lineage Wnt16 knock-out 
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mice32,34,35, showing that osteoblast-derived Wnt16 inhibits osteoclastogenesis34. Overexpression of Wnt16 in 
osteoblasts or osteocytes led to higher cortical as well as trabecular bone mass in mice and caused an increase 
in bone formation compared to controls36,37 suggesting that Wnt16 also promotes osteoblast differentiation and 
function, similar to other Wnt ligands38.
Several studies indicate that GCs suppress canonical Wnt signaling by reducing various signalling components 
such as cytosolic and nuclear abundance of β-catenin16,39,40 and gene expression of low-density lipoprotein 516,41. 
Concurrently, GCs increase the expression of Wnt inhibitors such as Dickkopf-116,42,43 and Wnt inhibitor factor 
144,45 suggesting that the inhibition of Wnt signaling may be a key mechanism of GC-induced suppression of bone 
formation. Despite the crucial role of Wnt16 in the regulation of bone homeostasis, the modulation of Wnt16 by 
GCs has not been studied so far. Thus, in this study, we tested the hypothesis that GCs inhibit bone formation via 
suppressing Wnt16 expression.
Methods
Declaration of approval for animal experiments. All experiments involving animals were approved 
by the Landesdirektion Sachsen, Germany and were performed in accordance with the relevant guidelines and 
regulations (approval number: TVV 86/2017).
Animals and induction of glucocorticoid-induced bone loss. Full GR knock-out mice (GR−/−) and 
mice with impaired GR dimerization (GRdim) were described previously13. Two different models of GC-induced 
bone loss were performed. In the first experiment, 24-week-old female FVB/N mice were used and received a 
3.5 mg prednisolone (n = 6) or placebo (n = 6) pellet (60 day release; Innovative Research of America, Inc.) for 
4 weeks. In the second experiment, 10-week-old female FVB/N mice received slow-release pellets with pred-
nisolone (PRED, n = 3) or placebo (n = 3) for 14 days (15 mg; 60 day release; Innovative Research of America, 
Inc.). Pellets were implanted subcutaneously and released a calculated prednisolone dose of 12.5 mg/kg/day. This 
resulted in a calculated dose of 2 mg/kg/day. Bone loss and suppression of bone formation was confirmed in both 
models and has been reported previously13,18. Animal protocols were approved by the Landesdirektion Sachsen, 
Germany.
Bone analysis. Trabecular bone mineral density was assessed in the distal femur by peripheral quantitative 
computed tomography (pQCT; Stratec, Pforzheim, Germany). The measurements were made with a voxel size 
of 70 µm at the distal femur (two slices at the trabecular region located 1 mm from the growth plate, one at the 
mid-diaphysis located 6 mm from the growth plate). For the measurement of trabecular bone mineral density, 
regions of interest were set. For contouring mode 1 and peel mode 20 were used. Quality control measurements 
were performed using the standard and cone phantom, which was supplied by the manufacturer.
In vivo calvarial model. Male 12-week-old C57BL/6j wildtype mice were injected subcutaneously with 
0.5 mg/kg dexamethasone (DEX, Sigma-Aldrich) or 0.5 mg/kg DEX and 500 ng recombinant human WNT16 
(Peprotech) three times per week, respectively, in a total volume of 25 µl. One group received 25 µl PBS injections 
as vehicle control. Five and 2 days before sacrifice, the mice received two intraperitoneal injections of calcein 
(20 mg/kg, Sigma-Aldrich). The mice were sacrificed after three weeks. Calvariae were fixed in 4% PBS-buffered 
paraformaldehyde and dehydrated in ascending ethanol series. Subsequently, calvariae were embedded in meth-
acrylate and cut into 7 µm sections to assess fluorescence labels using fluorescence microscopy. Bone formation 
rate per bone surface (BFR/BS) was determined using the Osteomeasure software (OsteoMetrics, Decatur, GA, 
USA).
Osteoblast cultures. Bone marrow was flushed from hind legs of C57BL/6 or GR mutant mice and seeded 
at a density of 1,000,000 cells per cm² in DMEM containing 10% fetal calf serum (FCS) and 1% penicillin/strep-
tomycin (Pen/Strep) (all from Invitrogen, Karlsruhe, Germany). At 70% confluence, cells were switched to differ-
entiation media with 5 mM β-glycerol phosphate and 100 µM ascorbate phosphate (all from Sigma-Aldrich) for 
7 days. Thereafter, cells were switched to starving media (DMEM containing 1% FCS and 1% Pen/Strep) over-
night and treated with DEX (Sigma-Aldrich) at concentrations as indicated in the figure legends for a maximum 
of 48 hours. In some experiments, cells were co-treated with 1 µM RU-486 (Sigma-Aldrich), an established GR 
antagonist.
Calvaria organ culture. Calvarial bones were isolated from 3–5 day old C57BL/6 pups and surrounding 
tissue was removed. Both halves were placed in a culture dish with DMEM containing 10% FCS and 1% Pen/
Strep. Calvariae were stimulated with 1 µM DEX or vehicle for 24 h. Thereafter, calvarial bones were used for RNA 
isolation as described below.
Alkaline phosphatase (ALP) assay. Cells were lysed in 100 µl lysis buffer (1.5 mM Tris-HCl pH 7, 1 mM 
ZnCl2, 1 mM MgCl2, 1% triton X-100) and centrifuged for 15 min at 6,000 rpm at 4 °C. Aliquots of each sam-
ple were incubated with 100 µl ALP substrate buffer (100 mM diethanolamine, 0.1% triton X-100 supplemented 
with 1:10 37 mM p-nitrophenylphosphate) for 30 min at 37 °C. The enzymatic reaction was stopped with 40 mM 
NaOH, measured at a wavelength of 405 nm, and normalized to the total protein content determined by the BCA 
method from the same protein extracts.
Promoter reporter assay. The GR binding site was identified as a transcriptional regulatory motif of the 
Wnt16 promoter region by the online search tool (http://RegRNA.mbc.NCTU.edu.tw/; http://tfbind.hgc.jp/) and 
the eukaryotic promoter database (http://epd.vital-it.ch/). In order to investigate activation of the Wnt16 pro-
moter by GR signalling, a dual-reporter assay using secreted Gaussia princeps luciferase (GLuc) under the control 
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of a Wnt16 promoter was applied (pEZX-PG04, Gene Copeia). The plasmid pEZX-PG04 also contains secreted 
alkaline phosphatase (SEAP) as a secondary reporter gene for transfection normalization.
MC3T3-E1 cells were seeded in a density of 1.5 × 104 cells per cm2 in basal medium (α-MEM, 10% FCS, 
2 mM glutamine and 1% PenStrep). When cells were 70–80% confluent, medium was changed to basal medium 
without antibiotics one hour before the transfection. pEZX-PG04 was diluted to a final concentration of 1 μg plas-
mid DNA/100 μl medium (0.01 μg/μl) with the reduced serum medium Opti-Minimal Essential Medium (Life 
Technologies). Transient transfections were performed using the liposome-mediated X-tremeGENE HP DNA 
(Roche) transfection reagent. The medium was changed to fresh standard basal medium 24 h after transfection 
and DEX (1 µM) treatment was performed. Supernatant was harvested for the GLuc and SEAP assay 24 and 48 h 
after the treatment and stored at −20 °C until usage. Luciferase activity was measured by using the Secrete-Pair 
Luminescence assay kit (Gene Copeia) according to the manufacturer´s high sensitivity protocol.
RNA isolation, RT and real-time PCR. RNA was extracted from mice hind legs by crushing them in 
liquid nitrogen and collecting the bone powder in Trifast (Peqlab, Erlangen, Germany). RNA from cultured cells 
was extracted by removing the medium and adding 1 mL Trifast to one well of a 6-well plate. RNA isolation 
was performed according to the manufacturer’s protocol. Five-hundred ng RNA were reverse transcribed using 
Superscript II (Life Technologies, Germany) and subsequently used for SYBR green-based real-time PCR reac-
tions using a standard protocol (Applied Biosystems, USA). Primer sequences were used as follows: mu β-actin 
(forward, 5′-GATCTGGCACCACACCTTCT-3′; reverse, 5′-TCCTGGGAGTGTAGGTTTGG-3′); mu Wnt16 
(forward, 5′-GGAGCTGTGCAAGAGGAAAC-3′; reverse,5′-AGTGGCGACCATACAGTTCC-3′); mu Ocn 
(forward, 5′- GCGCTCTGTCTCTCTGACCT-3′; reverse 5′- ACCTTATTGCCCTCCTGCTT-3′); mu ALP (for-
ward, 5′-CTACTTGTGTGGCGTGAAGG-3′; reverse, 5′- CTGGTGGCATCTCGTTATCC-3′). PCR conditions 
were 50 °C for 2 min and 95 °C for 10 min followed by 40 cycles with 95 °C for 15 s and 60 °C for 1 min. The melting 
curve as assessed in the following program: 95 °C for 15 s, 60 °C for 1 min and 95 °C for 30 s. The results were cal-
culated applying the ΔΔCT method and are presented in x-fold increase relative to β-actin.
Western Blot analysis. BMSCs were isolated from hind legs of wild type mice and seeded at a density of 1 
Mio. cells per cm² in DMEM containing 10% fetal FCS and 1% PenStrep. At 70% confluence, cells were switched 
to starving medium overnight. Cells were then treated with DEX (100 nM) for 48 hours. After removal of cell 
culture media, cells were lysed in 1 × RIPA lysis buffer (Cell Signaling Technology, Danvers, USA) and frozen 
at −80 °C. After thawing, samples were vortexed and centrifuged at 25,000 × g for 30 min at 4 °C. For Western 
Blot analysis, lysates were boiled for 5 min at 98 °C. Twenty μg of proteins were loaded on a 10% SDS-PAGE and 
transferred onto a 0.2 μm nitrocellulose membrane. After blocking for 1 h with 5% milk powder in Tris-buffered 
saline with 1% Tween-20 (TBS-T), membranes were incubated with antibodies against Wnt16 (1:500, Abcam, 
#ab109437) and GAPDH (1:2,000, Hytest, #5G4) overnight. After washing 3 times with TBS-T, incubation with 
an appropriate HRP-conjugated IgG antibody (1:2,000) for 1 h at RT followed. Proteins were visualized using 
the ECL Western-Blotting Substrate (Thermo Scientific). The chemiluminescence signal was recorded using a 
MF-ChemiBIS 3.2bio imager system (Biostep).
Statistical analysis. Results are presented as means ± standard deviation (SD). Statistical evaluations were 
performed using a Student’s t-test, one-way or two-way ANOVAs (with Dunn’s multiple comparison corrections) 
as indicated in the figure legends. P-values ≤ 0.05 were considered statistically significant.
Data availability. No large datasets were generated or analysed during this study. All other datasets analysed 
during this study are available from the corresponding author on reasonable request.
Results
Wnt16 is downregulated by glucocorticoids in osteoblasts. To investigate the effects of GCs on 
Wnt16 in osteoblasts, we treated murine osteoblasts derived from bone marrow stromal cells (mBMSCs) with 
increasing concentrations of DEX for different time periods. DEX led to a dose-dependent reduction of Wnt16 
expression, reaching a maximum at concentrations of 0.1 µM and 1 µM DEX, respectively (3.2-fold) (Fig. 1A). 
Furthermore, DEX suppressed Wnt16 expression in osteoblasts in a time-dependent manner with the strongest 
reduction after 48 h (2.5-fold) (Fig. 1B). The suppression of Wnt16 after DEX treatment was also apparent at 
protein level (Fig. 1C).
In order to further validate inhibition of Wnt16 expression by GCs we cultured calvaria of 3–5 day old mice 
with DEX for 24 h. Gene and protein expression analysis confirmed the inhibition of Wnt16 by GCs (Fig. 1D). 
DEX decreased Wnt16 mRNA levels and Wnt16 protein expression more than 2-fold than in the control.
Glucocorticoids reduce bone formation and Wnt16 expression in a model of GIO. To assess the 
effects of GCs on Wnt16 expression in vivo, we treated wildtype mice with the clinically used GC prednisolone for 
4 weeks. As expected, bone mineral density of femoral bone was significantly reduced by 25% (Fig. 2A). In line, 
prednisolone exposure inhibited bone formation by more than 70% as determined by dynamic histomorphom-
etry following dual calcein labelling (Fig. 2B). Accordingly, gene expression levels of osteoblastic markers in the 
femur of prednisolone-treated mice revealed a more than 2-fold downregulation of alkaline phosphatase (Alpl) 
and osteocalcin (Bglap) (Fig. 2C). In addition, expression of Wnt16 mRNA was diminished by more than 70% in 
the femur of prednisolone-treated mice (Fig. 2C). A similar suppression of bone formation and Wnt16 expression 
was observed in mice that were treated for 2 weeks with a higher dose of prednisolone (data not shown). Thus, 
these data indicate that Wnt16 expression is inhibited by GCs in vitro and in vivo.
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Wnt16 regulation by glucocorticoids is mediated by the GR and requires intact dimerization of 
the GR. We next elucidated the underlying mechanisms of GC-induced Wnt16 regulation. Since GCs mediate 
their effects via the GR, we first co-treated osteoblasts with DEX and the GR-antagonist RU-486. Application 
of RU-486 completely abolished the DEX-induced reduction of Wnt16 expression (Fig. 3A). RU-486 alone had 
no effect on Wnt16 mRNA levels. To confirm the involvement of the GR in mediating GC-induced effects on 
Wnt16 expression, we treated osteoblasts derived from GR-deficient mice (GR−/− mice) with DEX. Whereas 
Figure 1. Glucocorticoids suppress Wnt16 in vitro. (A–C) Bone marrow stromal cells derived from wildtype 
mice were differentiated towards osteoblasts for 7 days and treated with (A) various concentrations of 
dexamethasone (DEX) and (B) various durations. N = 4–12. Wnt16 gene expression was quantified using real-
time PCR. Beta-actin was used as housekeeping gene. (C) Cells were treated with 100 nM DEX or 48 h. Protein 
levels of Wnt16 and Gapdh were detected using Western blot. Two independent experiments are shown out of 
four. Each Western blot represents an own gel. Full gels are shown in Suppl. Fig. 1. (D) Calvarial bone from 3–5 
days old C57BL/6 pups were cultured for 24 h in the presence or absence of 1 µM DEX. Wnt16 gene expression 
was quantified using real-time PCR (n = 6); protein expression using Western blot (n = 4). Numbers indicate 
semi-quantification of Western blots. Each Western blot represents an own gel. Full gels are shown in Suppl. 
Fig. 1. *p < 0.05; **p < 0.01 using One-way ANOVA for (A,B) and t-test for (D).
Figure 2. Glucocorticoids reduce bone formation and Wnt16 expression in vivo. (A–C) 24-week-old female 
FVB/N mice received slow-release pellets with prednisolone (PRED) or placebo (CO) for 4 weeks (3.5 mg; 60 
day-release). (A) Bone mineral density (BMD) of the femoral bone was determined by using µCT and (B) bone 
formation rate per bone surface (BFR/BS) was quantified by dual calcein labeling following histomorphometry. 
(C) Gene expression levels of osteoblastic markers and Wnt16 was measured in the femoral bone of 
prednisolone treated mice by real-time PCR and normalized to untreated mice. N = 6. *p < 0.05; **p < 0.01 
using t-tests.
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DEX reduced Wnt16 expression in osteoblasts derived from wildtype mice, DEX failed to suppress Wnt16 in the 
absence of the GR (Fig. 3B).
The GR alters gene expression via different modes of action, including binding as a homodimer to GREs in 
the promotor of GC-target genes and interaction as a monomer with DNA-bound transcription factors such as 
NF-κB, AP-1, IRF-3 or STAT546. To further study the underlying mode of GR action in the regulation of Wnt16, 
we analysed mice with attenuated GR dimerization (GRdim mice47) that show reduced DNA binding as revealed by 
genome wide studies48. GRdim mice were treated with prednisolone for 14 days. In contrast to wildtype littermate 
control mice, in which prednisolone treatment reduced Wnt16 expression in femoral bone, prednisolone did not 
reduce skeletal Wnt16 expression in GRdim mice (Fig. 3C). Thus, intact GR dimerization and likely DNA binding 
of the GR is required for mediating GC effects on Wnt16 expression.
As these results suggested an involvement of direct DNA-binding mechanisms of the GR, we next searched 
for transcriptional GR regulatory motifs in the promotor of Wnt16 with the help of online search tools. Using 
three different websites, we identified multiple putative GR binding sites. Further, we performed a luciferase 
dual-reporter assay to verify the regulation of Wnt16 promoter activity via GCs. Following lipid-mediated trans-
fection of the Wnt16 promotor construct in the osteoblastic cell line MC3T3-E1, we treated the cells for 48 h with 
DEX. Luciferase activity was reduced up to 30% in DEX-treated cells (Fig. 3D) indicating that the GR directly 
binds GRE motifs in the Wnt16 promoter region.
Wnt16 rescues GC-induced suppression of bone formation. To assess the functional role of Wnt16 
in GC-induced suppression of osteoblast function and bone formation, we treated osteoblasts with DEX and/
or recombinant Wnt16 and measured alkaline phosphatase (ALP) activity. As shown in Fig. 4A, ALP activity 
Figure 3. Regulation of Wnt16 by glucocorticoids is mediated by DNA-binding mechanisms of the GR. (A) 
Bone marrow stromal cells derived from wildtype mice were differentiated towards osteoblasts for 7 days and 
treated with 1 µM DEX with or without addition of 1 µM RU-486, a GR antagonist. Wnt16 gene expression was 
measured by quantitative real-time PCR. N = 4–5. (B) GR-deficient osteoblasts were treated with 1 µM DEX 
and Wnt16 expression was determined by real-time PCR. N = 3. (C) 10-week-old female FVB/N wildtype and 
GR dimerization-deficient mice received slow-release pellets with prednisolone (PRED, 15 mg; 60 day-release) 
for 14 days and Wnt16 expression of the femoral bone was assessed by real-time PCR. N = 3. (D) MC3T3-E1 
cells were transfected with the Wnt16 promoter reporter construct (pEZX-PG04) containing Gaussia princeps 
luciferase (GLuc) under the control of a Wnt16 promoter and treated with 1 µM DEX. After 48 h the activity 
of GLuc was measured in the supernatants by luminescence. Values were normalized to secreted alkaline 
phosphatase and control (CO). N = 3. *p < 0.05; **p < 0.01 using two-way ANOVAs.
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was reduced more than 2-fold upon DEX treatment, but addition of Wnt16 abrogated GC-induced suppres-
sion of osteoblast function. To further investigate the involvement of Wnt16 in GC-mediated inhibition of bone 
formation in vivo, we treated wildtype mice with DEX and recombinant Wnt16, respectively, for 3 weeks by 
subcutaneous injection over the calvaria and determined the bone formation rate by dual calcein labelling. 
Histomorphometric analysis revealed a strong reduction in bone formation in DEX-treated animals. The con-
comitant treatment with Wnt16, however, rescued the DEX-induced repression of bone formation (Fig. 4B,C). 
Thus, Wnt16 is involved in GC-induced suppression of bone formation in vivo.
Discussion
GCs are frequently used to treat chronic inflammation. However, long-term GC treatment causes severe side 
effects on the skeleton and leads to an increased fracture risk mainly due to the sustained suppression of bone 
formation11. Recently Wnt16 has been linked to cortical bone thickness and fracture risk28–31,33 and has been rec-
ognized as a positive regulator of bone mass and strength32,34–36. In this study, we investigated whether Wnt16 is a 
target of GC action. We show that GCs suppress Wnt16 expression in vitro and in vivo and that Wnt16 exposure 
counteracts the inhibitory effects of GCs on osteoblast function.
Using primary mouse osteoblasts, we found that DEX reduces Wnt16 expression in a time- and 
dose-dependent manner. Moreover, DEX treatment also reduced Wnt16 protein levels in osteoblasts and calvaria 
organ cultures. These results are in line with other studies that have shown that increasing GC doses oppose Wnt 
signalling thereby attenuating osteoblast differentiation and function. In a study with murine osteoblasts, high 
doses of corticosterone reduced the expression of Wnt7b and Wnt1042. In contrast to Wnt7b and Wnt10b, Wnt16 
was not modulated by GCs in a biphasic fashion as also low doses negatively affected Wnt16 expression.
In order to investigate the effects of GCs on Wnt16 in vivo, a GIO mouse model was used. Treatment of mice 
with prednisolone for four weeks caused a reduction of BMD and inhibition of bone formation as described pre-
viously13,18. In this model, Wnt16 expression was reduced in the bone tissue of GC-treated mice, and coincided 
with the reduced expression of the pro-osteoblastic markers alkaline phosphatase and osteocalcin.
After showing that Wnt16 is a novel target of GC action in bone, we analysed the underlying molecular 
mechanism. GCs bind to the GR and mediate their function by binding as a homodimer to palindromic DNA 
sequences (so called GRE, glucocorticoid response elements), binding to GRE half-sites as a monomer or binding 
as a monomer to DNA-bound transcription factors and thereby modulate target gene transcription49. Whereas 
for most anti-inflammatory GC effects GR dimerization is essential50–52, suppression of bone formation is pro-
posed to be mediated by GR monomers interacting with the transcription factor AP-113. Our data show that 
Figure 4. Wnt16 counteracts GC-induced suppression of bone formation. (A) Bone marrow stromal cells 
derived from wildtype mice were differentiated towards osteoblasts for 7 days and treated with 1 µM DEX, 1 µg/
ml Wnt16 or both, respectively. Osteoblast function was assessed by measuring alkaline phosphatase (ALP) 
activity. N = 4–5. (B + C) 12-week-old C57BL/6 mice were treated with 0.5 mg/kg DEX alone or in combination 
with 500 ng recombinant Wnt16 for 3 weeks subcutaneously over the calvaria. (B) Bone formation rate per 
bone surface (BFR/BS) was measured by dual calcein labeling and subsequent histomorphometric analysis. 
(C) Representative calcein labels per group. Scale bar: 20 µm. N = 3–7. *p < 0.05; **p < 0.01 using two-way 
ANOVAs.
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the suppression of Wnt16 expression by GCs is dependent on GR dimerization and DNA binding of the GR 
complex. This is in contrast to GC-induced suppression of other osteoblastic genes and cytokines such as Runx2, 
Col1a1 or Il11, which is likely mediated by monomeric GR transrepression mechanisms13. However, a distinct 
mechanism of GC-induced direct transrepression via binding of GR to evolutionary-conserved cis-acting nega-
tive GC-responsive elements (IR nGREs) was described by Surjit et al.53. In contrast to tethered transrepression, 
nGRE-mediated gene repression is abolished by the GRdim mutation. Moreover, co-treatment with RU486 pre-
vented GC-induced IR GRE-mediated direct transrepression53. Thus, it is tempting to speculate that the Wnt16 
gene may also contain IR nGREs, especially as also other GC-regulated Wnt genes such as Wnt1, Wnt5a and 
Wnt10b contain putative IR nGREs53 and the number of genes regulated by nGREs has been proposed to be 
higher than previously thought. Additional evidence for the requirement of DNA-binding mechanisms of the 
GR is provided by in silico analyses, which identified GR transcriptional regulatory motifs in the Wnt16 pro-
moter region, and a promoter assay, which revealed a suppression of Wnt16 promoter activity after GC treatment. 
Finally, considering that Wnt16 expression was already regulated after 3 hours, our data suggest that Wnt16 is a 
primary response gene of GC signalling via direct GR DNA-binding mechanisms in osteoblasts. Further studies 
are necessary to explore the exact GR binding motifs within the putative negative GREs on the Wnt16 promoter.
After having established the regulatory role of GCs on Wnt16 expression, we addressed whether Wnt16 is able 
to rescue GC-induced suppression of bone formation. Interestingly, single treatment of both, primary osteoblasts 
and mice did not significantly alter osteoblast function, indicating that short-term treatment with Wnt16 may not 
be sufficient to enhance osteoblast function in the same way as long-term exposure as in WNT16 overexpressing 
mice36,37. Similarly, osteoblasts derived from Wnt16KO mice did not show alterations in their differentiation 
capacity34 However, co-treatment of osteoblasts with DEX and recombinant Wnt16 abrogated the GC-induced 
suppression of osteoblast function in vitro and in vivo. This novel finding suggests that restoring Wnt16 expression 
can at least partly abolish GC-induced suppression of bone formation in vitro and in vivo. One limitation of this 
study is the local treatment with DEX and Wnt16, despite GIO being a systemic disease. However, considering 
that Wnt ligands act in a local, paracrine fashion, we chose the local treatment of calvarial bone with DEX and 
Wnt16. This approach has also been taken in a previous study, in which inflammation-induced calvarial bone loss 
was rescued using recombinant Wnt1634. Future studies using Wnt16 overexpressing mice are underway that may 
provide more insights into the systemic rescue of GIO via Wnt1654,55.
Collectively, our data suggest that Wnt16 is a direct target of GC action and that restoration of Wnt16 alleviates 
GC-suppressed bone formation. Thus, Wnt16 may represent a novel target for therapeutic intervention in GIO.
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